Overview
Mylab and Serum Institute of India have launched Nasovac S4, the country's first needle-free nasal influenza vaccine, aiming to increase vaccination rates by offering a more comfortable alternative to traditional injections. The vaccine is a quadrivalent formulation, targeting four influenza virus strains, and is available for individuals over the age of 2 through private healthcare providers in India.
Nasovac S4 Vaccine Launch Details
- Mylab and Serum Institute of India collaborated to develop and launch Nasovac S4.
- Nasovac S4 is India's first nasal influenza vaccine, eliminating the need for needles.
- The vaccine contains four strains: two Type A (A/H1N1 and A/H3N2) and two Type B (Victoria and Yamagata).
- It is indicated for people above 2 years of age.
- The vaccine is administered as a single intranasal dose.
- Action begins in the nasal passages, stimulating antibody production for influenza defense.
Advantages and Objectives
- Nasovac S4 is designed to address the discomfort and fear associated with injections, especially among children and those with trypanophobia.
- The nasal delivery offers both local (nasal passage) and systemic (bloodstream) immune protection.
- The vaccine aligns with WHO recommendations for influenza immunization.
- The launch aims to improve vaccine accessibility and boost overall influenza vaccination rates in India.
Availability and Distribution
- Nasovac S4 is currently available only in the private market across India.
- Distribution and marketing are managed through a partnership between Mylab and Serum Institute of India.
- The vaccine will be offered via healthcare providers and clinics nationwide.
Expert and Executive Statements
- Hasmukh Rawal, Managing Director of Mylab, emphasized the partnership's goal to provide comprehensive protection against multiple influenza strains.
- Dr. Rajeev Dhere, Executive Director at Serum Institute, highlighted the two-level immune response of the nasal vaccine, protecting both at the entry site and systemically.
Recommendations / Advice
- Vaccination remains the primary defense against influenza and is recommended for all eligible individuals.
- Nasal influenza vaccines can provide a more accessible and comfortable immunization option, particularly for children and needle-averse individuals.